Replies to post #69082 on Innovation Pharmaceuticals Inc (IPIX)

[noretreat]

We will have an update with the next quarterly report.

[John B]

Oddone, as far as CTIX capital. This is a rough swag based on a previous post I did at the end of March:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=99695227

As of 12/31/13 we had 5 mill in cash, and 20 mill available yet from the new Aspire deal for a total of 25 million.

From the March 10Q the cost of the five clinical trials will be about 12 million:
Clinical trials - $11,850,000. We have budgeted $1,350,000 for our Phase 1 Kevetrin trials; $3,000,000 for the planned Prurisol phase 1 crossover study and phase 2/3 trials; $4,500,000 for the planned Brilicidin ABSSSI Phase 2b trials; and $3,000,000 for the planned Brilicidin Oral Mucositis Phase 2 trials.

They budgeted 4 million in other costs for the next 12 months:
R&D $1,200,000, overhead $2,500,000, and Capital costs of $100,000.
If you figure we spent 3 mill in the first three quarters then:

25 million minus 12 million for trials, minus 3 million = 10 million left in capital to work with yet.

Obviously the 10 million can't all be used for future trials. We need to maintain 4 million on the balance sheet for uplisting, and would want another 4 million available for operations over the next 9 months or so.
This leaves only 2 million for future trials like B-ABSSSI Phase 3. So we can start this trial, but it looks like we will need to raise money or get a partnership, by sometime in the first 6 months of 2015.
Hope this helps.